443 related articles for article (PubMed ID: 25483669)
1. Engineering better immunotherapies via RNA interference.
Sioud M
Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
3. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.
Sioud M; Mobergslien A; Sæbøe-Larssen S
Methods Mol Biol; 2015; 1218():269-76. PubMed ID: 25319657
[TBL] [Abstract][Full Text] [Related]
5. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Zheng X; Koropatnick J; Chen D; Velenosi T; Ling H; Zhang X; Jiang N; Navarro B; Ichim TE; Urquhart B; Min W
Int J Cancer; 2013 Feb; 132(4):967-77. PubMed ID: 22870862
[TBL] [Abstract][Full Text] [Related]
6. Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference.
Sioud M
Methods Mol Biol; 2020; 2115():259-280. PubMed ID: 32006406
[TBL] [Abstract][Full Text] [Related]
7. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.
Sioud M; Saebøe-Larssen S; Hetland TE; Kaern J; Mobergslien A; Kvalheim G
Int J Oncol; 2013 Jul; 43(1):280-8. PubMed ID: 23620105
[TBL] [Abstract][Full Text] [Related]
8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
9. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
[TBL] [Abstract][Full Text] [Related]
10. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
12. The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy.
Endo R; Nakamura T; Kawakami K; Sato Y; Harashima H
Sci Rep; 2019 Aug; 9(1):11335. PubMed ID: 31383907
[TBL] [Abstract][Full Text] [Related]
13. A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem.
Zhang Y; Fu J; Shi Y; Peng S; Cai Y; Zhan X; Song N; Liu Y; Wang Z; Yu Y; Wang Y; Shi Q; Fu Y; Yuan K; Zhou N; Joshi R; Ichim TE; Min W
Int J Cancer; 2018 Oct; 143(8):2039-2052. PubMed ID: 29752722
[TBL] [Abstract][Full Text] [Related]
14. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.
Conroy H; Galvin KC; Higgins SC; Mills KH
Cancer Immunol Immunother; 2012 Mar; 61(3):425-31. PubMed ID: 22193988
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
16. Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase.
Flatekval GF; Sioud M
Immunology; 2009 Sep; 128(1 Suppl):e837-48. PubMed ID: 19740345
[TBL] [Abstract][Full Text] [Related]
17. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
18. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
19. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
Heo MB; Cho MY; Lim YT
Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effects and mechanisms of a dendritic cell vaccine which silenced SOCS1 by siRNA, stimulated by OK-432 and pulsed with lysate of HepG2 cells].
Song HF; Zhou J; Pan K; Wang QJ; Wang H; Huang LX; Li YQ; Xia JC
Ai Zheng; 2008 Jul; 27(7):685-91. PubMed ID: 18606059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
